Abstract
Background: Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably.
Methods: In this review, we describe the structural features of IL-12 family and their roles involved in cancer.
Results: IL-12 has been demonstrated to regulate both innate (natural killer cells) and adaptive (cytotoxic T lymphocytes) immunities in cancer therapy. This cytokine has been proposed as a potential new agent to be developed in cancer immunotherapy studies due to its impressive antitumor effects in many animal models. In addition, the antitumor activity of IL-12 can be efficiently induced by itself as well as significantly improved by its combination with various treatment modalities including antibodies, antiangiogenic agents, radiotherapy, adoptive therapy, and anti-tumor vaccines.
Conclusion: IL-12 has potential roles in anticancer therapy. The advantages of using immunotherapeutic approaches in clinical trials have been reported recently. However, the mechanisms to underlay the immunoregulation and antitumor activities of IL-12 itself, as well as its combination, remain under investigation.
Keywords: IL-12, NK cells, cancer, Th1 pathway, receptor, immunotherapy.
Current Cancer Drug Targets
Title:Impact of IL-12 in Cancer
Volume: 17 Issue: 8
Author(s): Xinjie Lu*
Affiliation:
- Mary and Garry Weston Molecular Immunology Laboratory, Thrombosis Research Institute, London, SW3 6LR,United Kingdom
Keywords: IL-12, NK cells, cancer, Th1 pathway, receptor, immunotherapy.
Abstract: Background: Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably.
Methods: In this review, we describe the structural features of IL-12 family and their roles involved in cancer.
Results: IL-12 has been demonstrated to regulate both innate (natural killer cells) and adaptive (cytotoxic T lymphocytes) immunities in cancer therapy. This cytokine has been proposed as a potential new agent to be developed in cancer immunotherapy studies due to its impressive antitumor effects in many animal models. In addition, the antitumor activity of IL-12 can be efficiently induced by itself as well as significantly improved by its combination with various treatment modalities including antibodies, antiangiogenic agents, radiotherapy, adoptive therapy, and anti-tumor vaccines.
Conclusion: IL-12 has potential roles in anticancer therapy. The advantages of using immunotherapeutic approaches in clinical trials have been reported recently. However, the mechanisms to underlay the immunoregulation and antitumor activities of IL-12 itself, as well as its combination, remain under investigation.
Export Options
About this article
Cite this article as:
Lu Xinjie *, Impact of IL-12 in Cancer, Current Cancer Drug Targets 2017; 17 (8) . https://dx.doi.org/10.2174/1568009617666170427102729
DOI https://dx.doi.org/10.2174/1568009617666170427102729 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Central Regulatory Role of Cytokines in Periodontitis and Targeting Options
Current Medicinal Chemistry Obesity-Enhanced Colon Cancer: Functional Food Compounds and their Mechanisms of Action
Current Cancer Drug Targets Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities
Cardiovascular & Hematological Disorders-Drug Targets Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective
Current Topics in Medicinal Chemistry Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) A State-of-the-Art Review on Opioids Induced Constipation and its Management
Current Indian Science Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology Mitochondrial Signal Transduction Abnormalities in Systemic Lupus Erythematosus
Current Immunology Reviews (Discontinued) Homologous Recombination, Non-Homologous End-Joining and Cell Cycle: Genomes Angels
Current Genomics Inhibition of microRNA-155 Alleviates Cognitive Impairment in Alzheimer’s Disease and Involvement of Neuroinflammation
Current Alzheimer Research Plant Polysaccharides with Immunostimulatory Activities
Current Organic Chemistry (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Controlled Delivery of Bioactive Molecules for the Treatment of Chronic Wounds
Current Pharmaceutical Design Ligament and Tendon Repair through Regeneration Using Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Cancer and the Endogenous “Pineal Clock”: A Means of Early Diagnosis and Successful Treatment as Well as Prevention of Cancers
Current Aging Science Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)